Abstract
We have utilized multicolored fluorescent proteins to develop three imaging models of tumor angiogenesis. In one model, the nonluminous induced capillaries are clearly visible by contrast against the very bright tumor green fluorescent protein (GFP) fluorescence examined either intravitally or by whole-body imaging in real time. Intravital images of an orthotopic model of human pancreatic tumors expressing GFP visualized angiogenic capillaries at both primary and metastatic sites. Whole-body optical imaging showed that blood vessel density increased linearly over a 20-week period in an orthotopic model of human breast cancer expressing GFP. Opening a reversible skin-flap in the light path markedly reduces signal attenuation, increasing detection sensitivity many-fold and enables vessels to be externally visualized in GFP-expressing tumors growing on internal organs. In another model, dual-color fluorescence imaging was effected by using red fluorescent protein (RFP)-expressing tumors growing in GFP-expressing transgenic mice that express GFP in all cells. This dual-color model visualizes with great clarity the details of the tumor-stroma interaction, especially tumorinduced angiogenesis. The GFP-expressing tumor vasculature, both nascent and mature, are readily distinguished interacting with the RFP-expressing tumor cells. The third model involves a transgenic mouse in which the regulatory elements of the stem cell marker nestin drive GFP (ND-GFP). The ND-GFP mouse expresses GFP in nascent blood vessels. RFPexpressing tumors transplanted to nestin-GFP mice enable specific visualization of nascent vessels. The ND-GFP mouse was utilized to develop a rapid in vivo/ex vivo fluorescent angiogenesis assay by implanting Gelfoam which was vascularized by fluorescent nascent blood vessels. This process could be markedly stimulated or inhibited by specific compounds. We also observed, using ND-GFP mice, that the hair follicle is angiogenic and that the hair-follicle vascular network is a prime target for chemotherapy drugs which cause hair loss (chemotherapy-induced alopecia). These fluorescent models, generally termed AngioMouse®, can quantitatively determine efficacy of antiangiogenesis compounds.
Keywords: Green fluorescent protein, red fluorescent protein, nude mouse, human tumors, imaging, nascent blood vessels
Current Pharmaceutical Design
Title: Color-Coded Fluorescent Protein Imaging of Angiogenesis: The AngioMouse® Models
Volume: 14 Issue: 36
Author(s): Yasuyuki Amoh, Kensei Katsuoka and Robert M. Hoffman
Affiliation:
Keywords: Green fluorescent protein, red fluorescent protein, nude mouse, human tumors, imaging, nascent blood vessels
Abstract: We have utilized multicolored fluorescent proteins to develop three imaging models of tumor angiogenesis. In one model, the nonluminous induced capillaries are clearly visible by contrast against the very bright tumor green fluorescent protein (GFP) fluorescence examined either intravitally or by whole-body imaging in real time. Intravital images of an orthotopic model of human pancreatic tumors expressing GFP visualized angiogenic capillaries at both primary and metastatic sites. Whole-body optical imaging showed that blood vessel density increased linearly over a 20-week period in an orthotopic model of human breast cancer expressing GFP. Opening a reversible skin-flap in the light path markedly reduces signal attenuation, increasing detection sensitivity many-fold and enables vessels to be externally visualized in GFP-expressing tumors growing on internal organs. In another model, dual-color fluorescence imaging was effected by using red fluorescent protein (RFP)-expressing tumors growing in GFP-expressing transgenic mice that express GFP in all cells. This dual-color model visualizes with great clarity the details of the tumor-stroma interaction, especially tumorinduced angiogenesis. The GFP-expressing tumor vasculature, both nascent and mature, are readily distinguished interacting with the RFP-expressing tumor cells. The third model involves a transgenic mouse in which the regulatory elements of the stem cell marker nestin drive GFP (ND-GFP). The ND-GFP mouse expresses GFP in nascent blood vessels. RFPexpressing tumors transplanted to nestin-GFP mice enable specific visualization of nascent vessels. The ND-GFP mouse was utilized to develop a rapid in vivo/ex vivo fluorescent angiogenesis assay by implanting Gelfoam which was vascularized by fluorescent nascent blood vessels. This process could be markedly stimulated or inhibited by specific compounds. We also observed, using ND-GFP mice, that the hair follicle is angiogenic and that the hair-follicle vascular network is a prime target for chemotherapy drugs which cause hair loss (chemotherapy-induced alopecia). These fluorescent models, generally termed AngioMouse®, can quantitatively determine efficacy of antiangiogenesis compounds.
Export Options
About this article
Cite this article as:
Amoh Yasuyuki, Katsuoka Kensei and Hoffman M. Robert, Color-Coded Fluorescent Protein Imaging of Angiogenesis: The AngioMouse® Models, Current Pharmaceutical Design 2008; 14 (36) . https://dx.doi.org/10.2174/138161208786898644
DOI https://dx.doi.org/10.2174/138161208786898644 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Structural and Bioactive Properties of 3-O-Methylfunicone
Mini-Reviews in Medicinal Chemistry Synthesis and Anticancer Activity of Thiadiazole Containing Thiourea, Benzothiazole and Imidazo[2,1-b][1,3,4]thiadiazole Scaffolds
Medicinal Chemistry A Series of 2,4(1H,3H)-Quinazolinedione Derivatives: Synthesis and Biological Evaluation as Potential Anticancer Agents
Letters in Drug Design & Discovery Glioblastoma Multiforme and its Cell Interruption
Current Cancer Therapy Reviews Targeting FGFR with BGJ398 in Breast Cancer: Effect on Tumor Growth and Metastasis
Current Cancer Drug Targets Phytochemical and Pharmacological Overview of Triticum aestivum: An Update
Current Traditional Medicine Sp/KLF Family and Tumor Angiogenesis in Pancreatic Cancer
Current Pharmaceutical Design DNA Damage Repair and Response Proteins as Targets for Cancer Therapy
Current Medicinal Chemistry Intratumoral and Peritumoral Edema Radiomics Based on Fat-Suppressed T2- Weighted Imaging for Preoperative Prediction of Triple-Negative Breast Cancer
Current Medical Imaging Association between Statins Types with Incidence of Liver Cancer: An Updated Meta-analysis
Current Medicinal Chemistry Nitroimidazole Radiopharmaceuticals in Hypoxia: Part II Cytotoxicity and Radiosensitization Applications
Current Radiopharmaceuticals Development of Highly Efficient KinExA Immunosensor-Based Assay for the Measurement of Carcinoembryonic Antigen in Serum
Current Analytical Chemistry Anti-IL-12/23 in Crohn's Disease: Bench and Bedside
Current Drug Targets Editorial (Thematic Issue: Improving Cancer Clinical Research and Trials with Hispanic Populations: Training and Outreach Efforts Between Moffitt Cancer Center and the Ponce School of Medicine)
Reviews on Recent Clinical Trials Genetic and Epigenetic Signatures in Human Hepatocellular Carcinoma:A Systematic Review
Current Genomics Effect of Vinca Alkaloids on the Expression Levels of microRNAs Targeting Apoptosis-related Genes in Breast Cancer Cell Lines
Current Pharmaceutical Biotechnology Solid Lipid Nanoparticles: An Innovative Nano-Vehicles for Drug Delivery
Nanoscience & Nanotechnology-Asia Molecular Dynamics Mechanisms of the Inhibitory Effects of Abemaciclib, Hymenialdisine, and Indirubin on CDK-6
Current Drug Research Reviews Challenges and Opportunities for Clinical Research in the Middle East
Applied Clinical Research, Clinical Trials and Regulatory Affairs Cytokines as Potential Therapeutic Targets and their Role in the Diagnosis and Prediction of Cancers
Current Pharmaceutical Design